EUVIMEDObjevte EUVIMED
EUVIMED · CrossrefJournal

Annals of Oncology

ISSN 0923-7534 · Elsevier BV

Latest articles

  1. Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)

    A.Y. Zhang, H. Thomas, S. Begbie, L. Cheung, K.N. Chi, S. Chowdhury, M. Frydenberg, C. Herberstein, L.G. Horvath, A.M. Joshua, N.J. Lawrence, G. Marx, J. McCaffrey, R. McDermott, R.A. McLaughlin, S.A. North, F. Parnis, W. Parulekar, D.W. Pook, M.N. Reaume, S.K. Sandhu, A. Tan, T.H. Tan, A. Thomson, F. Vera-Badillo, S.G. Williams, R.R. Zielinski, M.R. Stockler, I.D. Davis, C.J. Sweeney

    Published: 2026-11DOI: 10.1016/j.annonc.2026.07.412

  2. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial

    J.E. Garber, D. Cameron, C. Campbell, G. Yothers, M. Taboada, S. El-Abed, P. Rastogi, R. McConnell, A. Correa, S. Delaloge, W.T. Liu, P. Sharma, J. Bergh, W. Janni, J. Balmaña, N. Loman, T. Španić, S. Friedman, T. Freeman, A. Armstrong, L. Korde, S. Im, Y. Sagara, G. Viale, J. Bliss, L. Gianni, Ó. Jóhannsson, G. Zoppoli, E. Martinez De Dueñas, F. Marmé, L. Fein, M. Arnedos, J. Ford, R. Schmutzler, S. Loibl, B. Linderholm, S.R. Lakhani, M. Gnant, K. Gelmon, S.M. Domchek

    Published: 2026-11DOI: 10.1016/j.annonc.2026.08.002

  3. Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer

    F. Facchinetti, L. Friboulet, L. Liao, M. Peroni, S. Nakazawa, L. Zullo, M. Aldea, F. Pecci, M. Makarem, I. Alonso Garcia, R. Minari, B. Tuladhar, K. Ngo, A. Da Silva, L. Bigot, I. Odintsov, M.K.A. Koivu, A. Leonetti, J. Samaniego, E. Bernard, D.J. Kwiatkowski, B. Ricciuti, J.K. Rotow, J. Luo, J. LoPiccolo, N. Florez, M.M. Awad, J. Remon, Y. Loriot, B. Besse, F. Barlesi, A. Italiano, D.A. Barbie, C.P. Paweletz, P.C. Gokhale, W.W. Feng, M. Tiseo, D. Planchard, A.T. Shaw, P.A. Jänne

    Published: 2026-11DOI: 10.1016/j.annonc.2026.08.004

  4. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer

    P.A. Francis, O. Pagani, G.F. Fleming, B.A. Walley, M. Colleoni, G. Rubovszky, C. Tondini, E.M. Ciruelos, H.L. Gomez, H.R. Bonnefoi, H.J. Burstein, C. Chini, F. Puglisi, S. Spazzapan, A. Bernardo, M.A. Climent, M. Bellet, T. Ruhstaller, B. Bermejo, S.K.L. Chia, S. Martino, C.E. Geyer, M.P. Goetz, J.N. Ingle, V. Stearns, N.E. Davidson, F. Le Du, B. Müller, R.E. Coleman, S. Loibl, E.P. Winer, B. Ruepp, S. Loi, I. Láng, A.S. Coates, R.D. Gelber, A. Goldhirsch, M.M. Regan, M. Colleoni, S. Loi

    Published: 2026-10DOI: 10.1016/j.annonc.2026.05.704

  5. SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer

    A.C. Garrido-Castro, S.E. Kim, T. Li, J. Desrosiers, R. Nanda, Y. Abdou, A.S. Clark, R.L. Sacks, T. O’Connor, N. Sinclair, S. Lo, G. Augdahl, E. Wrabel, M. DiLullo, T. Rahman, A. Patel, M.E. Hughes, J. Baginska, P.B. Lange, T. O’Meara, T.E. Keenan, A. Gorthi, A. D’Ippolito, C.A. Painter, M. Eaton, J.C. Barrett, B. Koca, P.T. Kurnia, A.N. Perry, J. Gomez Tejeda Zanudo, M. He, D.A. Dillon, N.U. Lin, H.J. Burstein, E.A. Mittendorf, R. Jeselsohn, D.L. Rimm, N. Tayob, S.M. Tolaney

    Published: 2026-10DOI: 10.1016/j.annonc.2026.06.012

  6. Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW

    S. Lonardi, H.-J. Lenz, E. Elez, L.H. Jensen, E. Van Cutsem, Y. Touchefeu, R. Garcia-Carbonero, D. Tougeron, G.A. Mendez, M. Schenker, C. de la Fouchardière, M.L. Limón Mirón, T. Yoshino, J. Li, J.L. Manzano Mozo, L. Dahan, G. Tortora, M. Chalabi, E. Goekkurt, M.I. Braghiroli, R. Joshi, T. Cil, F. Aubin, V. Raparthi, A. Wang, S. Rodriguez, E. Cela, L. Li, R. Tam, L. Jin, T. André

    Published: 2026-10DOI: 10.1016/j.annonc.2026.09.009

  7. Post-operative ctDNA dynamics and eligibility for treat-on-molecular result (TOMR) ALTAIR trial in colorectal cancer: insights from CIRCULATE-Japan

    Y. Nakamura, H. Bando, V.N. Aushev, J. Watanabe, Y. Takahashi, M. Kotaka, N. Matsuhashi, E. Oki, Y. Komatsu, M. Shiozawa, K. Hirata, Y. Miyamoto, M. Takahashi, K. Yamazaki, D. Manaka, A. Kanazawa, Y.H. Liang, K.H. Yeh, C.C. Palsuledesai, R.W. Lentz, A. Jurdi, M.C. Liu, M. Rabinowitz, S. Mishima, I. Takemasa, D. Kotani, A. Sato, T. Misumi, H. Taniguchi, T. Yoshino, T. Kato

    Published: 2026-10DOI: 10.1016/j.annonc.2026.09.016

  8. Sofetabart mipitecan, an antibody–drug conjugate targeting folate receptor alpha, in high-grade ovarian cancer: results from the first-in-human phase I study

    I. Ray-Coquard, D.M. O’Malley, A. Oaknin, A. Madariaga, N. Lakhani, W.B. McKean, A. Perez-Fidalgo, M. Okera, S. Kitano, T. Koyama, J.S. Frenel, G. Curigliano, M.R. Khawaja, M.C. Lim, D. Lorusso, V. Pilla Reddy, R.M. Speck, A.M. Gilligan, A.M. Szpurka, M. Manvelyan, Y. Wu, C. Wang, E. Avsar, C.F. Friedman, D. Sachdeva, C. Kyi, B. Pothuri

    Published: 2026-10DOI: 10.1016/j.annonc.2026.10.001

  9. Final analysis of the Neotorch study: perioperative toripalimab in combination with chemotherapy for patients with stage Ⅱ/Ⅲ resectable non-small-cell lung cancer

    Z.M. Li, L. Wu, W.X. Wang, L.H. Sun, P. Zhang, W.T. Fang, Y. Zheng, Q.X. Chen, L. Yang, L.J. Tan, J.D. Mei, J.L. Shan, S.D. Xu, X.H. Sun, N. Yang, X.H. Hu, G.H. Yu, D.L. Yu, Y.P. Chen, L.G. Xing, Y.P. Liu, H. Tian, K.N. Chen, N. Wu, L.J. Cao, M. Zhou, H.H. Fang, X. Zhang, J. Jiang, X.Y. Li, M.Q. Kang, M.H. Ye, Q. Sun, S.Q. Li, G.W. Wu, H.P. Xu, K.S. Zhu, A.H. Zhong, L.M. Zhu, C.L. Wang

    Published: 2026-10DOI: 10.1016/j.annonc.2026.10.094

Volumes

2026 · 1,1832025 · 5,4172024 · 4,0812023 · 4,2972022 · 4,1692021 · 3,5592020 · 3,7712019 · 4,8272018 · 4,1002017 · 4,4342016 · 4,4432015 · 2,8282014 · 3,0172013 · 1,6382012 · 3,6772011 · 6822010 · 7522009 · 5872008 · 7882007 · 6592006 · 6912005 · 6102004 · 4962003 · 4402002 · 5282001 · 6822000 · 6611999 · 7921998 · 5881997 · 5641996 · 5671995 · 4261994 · 5201993 · 4181992 · 4631991 · 3441990 · 197

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.